Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/biomedicines6010035 http://scihub22266oqcxt.onion/10.3390/biomedicines6010035 C5874692!5874692 !29562667     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29562667 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Biomedicines 2018 ; 6 (1 ): ä Nephropedia Template TP {{tp|p=29562667 |t=2018. VHL and Hypoxia Signaling: Beyond HIF in Cancer |pdf=|usr=}}{{29562667 }} gab.com Text VHL and Hypoxia Signaling: Beyond HIF in Cancer JO: Biomedicines http://www.kidney.de/pget.php?&tw=1&pmid=29562667 #FOAvip Von Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor ? (including HIF1? and HIF2?) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF-?B signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer. Twit Text FOAVip VHL and Hypoxia Signaling: Beyond HIF in Cancer ????Biomedicines http://www.kidney.de/pget.php?&tw=1&pmid=29562667 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29562667 #FOAvip English Wikipedia <ref>{{Cite pmid|29562667 }}</ref> VHL and Hypoxia Signaling: Beyond HIF in Cancer #MMPMID29562667 Zhang J ; Zhang Q Biomedicines 2018[Mar]; 6 (1 ): ä PMID29562667 show ga Von Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor ? (including HIF1? and HIF2?) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF-?B signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer. äVHL and Hypoxia Signaling: Beyond HIF in Cancer (epmc).pdf DeepDyve Pubget Overpricing